Sugi Predict

Sugi Predict / Compounds / SCHEMBL3219986

SCHEMBL3219986

SCHEMBL3219986

CC(C)(C)OC(=O)N1C[C@H](F)C[C@H]1C(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ FKBP1A P62942 6/20 0.46
▸ KLK7 P49862 1/20 0.44
▸ ABCB1 P08183 1/20 0.43
▸ PDK1 Q15118 1/20 0.42
▸ PDK2 Q15119 1/20 0.42
▸ PDK3 Q15120 1/20 0.42
▸ PDK4 Q16654 1/20 0.42
▸ PARP1 P09874 1/20 0.42
▸ CTSL P07711 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16391281 1.00 FKBP1A (0.46) FKBP1AKLK7ABCB1PDK1PDK2
SCHEMBL5964137 1.00 FKBP1A (0.46) FKBP1AKLK7ABCB1PDK1PDK2
SCHEMBL3219990 1.00 FKBP1A (0.46) FKBP1AKLK7ABCB1PDK1PDK2
SCHEMBL19388768 1.00 FKBP1A (0.46) FKBP1AKLK7ABCB1PDK1PDK2
SCHEMBL3469910 0.91 PDK1 (0.47) FKBP1APDK1PDK2PDK3PDK4
SCHEMBL19920574 0.89 FKBP1A (0.49) FKBP1APDK1PDK2PDK3PDK4
SCHEMBL17893034 0.88 FKBP1A (0.51) FKBP1AKLK7ABCB1PDK1PDK2
SCHEMBL8332542 0.88 FKBP1A (0.51) FKBP1AKLK7ABCB1PDK1PDK2
SCHEMBL17896181 0.88 FKBP1A (0.51) FKBP1AKLK7ABCB1PDK1PDK2
SCHEMBL1449334 0.87 POLB (0.53) FKBP1AKLK7ABCB1PDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2026-01-27 — — US disclosed
EP-4676930-A1 METHODS FOR PREPARING PYRROLIZIDINE COMPOUNDS Frontier Medicines Corporation (US) 2026-01-14 — — EP disclosed
US-20250388536-A1 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS HOFFMANN-LA ROCHE INC. (US) 2025-12-25 — — US disclosed
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-12-10 — — US disclosed
CN-118871422-A 3-Alkynyl carboxamides as AEP modulators 豪夫迈·罗氏有限公司 2024-10-29 — — CN disclosed
WO-2024186680-A1 METHODS FOR PREPARING PYRROLIZIDINE COMPOUNDS FRONTIER MEDICINES CORPORATION (US) 2024-09-12 — — WO disclosed
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-07-25 — — US disclosed
EP-4308095-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2024-01-24 — — EP disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 — — US disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 — — US disclosed
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 — — US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 — — EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 — — US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 — — WO disclosed
US-20100036119-A1 FLUORINATING REAGENTS AND THEIR PREPARATION LANXESS DEUTSCHLAND GMBH (DE) 2010-02-11 — — US disclosed
US-7122521-B2 COMPRISING TRIPEPTIDE UNIT OF THE FORMULA (flp-Yaa-Gly)N, WHERE Yaa IS ANY AMINO ACID, FLP IS 4(R)-FLUORO-L-PROLINE, AND N IS AT LEAST 3; INCREASED STABILITY; STRONGER TRIPLE HELIX THAN NATIVE COLLAGEN; FOR USE SUCH AS IN ARTIFICIAL SKIN WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2006-10-17 — — US disclosed
US-20050085474-A1 Fluorinating reagents and their preparation LANXESS DEUTSCHLAND GMBH (DE) 2005-04-21 — — US disclosed
US-20050004032-A1 Collagen mimics NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-01-06 — — US disclosed
EP-1437342-A2 Fluorinating reactants and process for their preparation Bayer Chemicals AG (DE) 2004-07-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL FKBP1A 935/4885KLK7 3948/4885ABCB1 3077/4885
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS FKBP1A 346/4885KLK7 4127/4885ABCB1 526/4885
US-20250388536-A1 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS CNR2, CNR1, FAAH2 FKBP1A 3000/4885KLK7 4785/4885ABCB1 1259/4885
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 FKBP1A 1981/4885KLK7 718/4885ABCB1 818/4885
US-20050085474-A1 Fluorinating reagents and their preparation FLNA, ARFGEF1, FLNB FKBP1A 4870/4885KLK7 792/4885ABCB1 2623/4885
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS1, GYS2, GBA1 FKBP1A 2052/4885KLK7 4692/4885ABCB1 2372/4885
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF GYS2, GYS1, PYGL FKBP1A 935/4885KLK7 3948/4885ABCB1 3077/4885
US-20100036119-A1 FLUORINATING REAGENTS AND THEIR PREPARATION FLNA, ARFGEF1, FLNB FKBP1A 4870/4885KLK7 792/4885ABCB1 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.